Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline
TheFly reported on March 17 that JPMorgan increased its price target for EWTX from $34 to $45 while keeping an Overweight rating on the stock.
Edgewise Therapeutics Inc. (EWTX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 15,518,492 | $385,091,379 | 7.86% | |
| 2. | RA Capital Management Peter Kolchinsky | 10,428,437 | $258,781,664 | 2.65% | |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 6,575,940 | $163,181,951 | -10% | 0.96% |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 6,541,210 | $162,320,126 | +7% | 4.14% |
| 5. | Braidwell LP Alex Karnal | 5,210,831 | $129,306,771 | 4.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.64 | 10,700 | $199,403.06 | 23,702 | 2025-11-11 | Filing | |
| $20.13 | 124,193 | $2,500,005.09 | 443,792 | 2025-04-03 | Filing | |
| $20.13 | 372,578 | $7,499,995.14 | 14,809,075 | 2025-04-03 | Filing | |
| $20.13 | 124,193 | $2,500,005.09 | 443,792 | 2025-04-03 | Filing | |
| $20.13 | 372,578 | $7,499,995.14 | 14,809,075 | 2025-04-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.57 | 50,000 | $1,928,400.00 | 4,367 | 2026-05-05 | Filing | |
| $31.29 | 5,230 | $163,662.91 | 4,367 | 2026-05-04 | Filing | |
| $32.31 | 28,662 | $926,095.02 | 9,597 | 2026-04-01 | Filing | |
| $32.12 | 21,338 | $685,308.28 | 9,597 | 2026-03-31 | Filing | |
| $30.98 | 6,735 | $208,635.48 | 9,597 | 2026-03-27 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,788,161 | $119,327,072 | 0% | |
| 2. | 1,311,125 | $41,300,438 | 0.01% | |
| 3. | 1,219,717 | $38,412,551 | 0.01% | |
| 4. | 826,059 | $26,020,859 | 0.04% | |
| 5. | 557,260 | $17,553,690 | 0% |
News See All
13 Best Stocks to Invest In on Robinhood for Beginners
MacroMicro reports that as of March 18, 2026, the S&P 500's forward 12-month P/E was 21.35, which was far higher than its 10-year historical average of 18.9 but slightly lower than the 22.0x reported ...
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026
On the other hand, Edgewise Therapeutics, Inc.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 results on November 6, 2025. The quarter marked continued advancement of its muscular dystrophy and cardiac programs.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C.
11 Best Small Cap Stocks with the Highest Upside
She stated that small caps show possibility, as a lot of them are rate sensitive, a little bit more levered, and are helped by lower rates, which is why there has been a lot of momentum behind small caps...
Raymond James Initiates Strong Buy on Edgewise Therapeutics (EWTX) with $46 PT, Cites EDG-7500 Potential for HCM
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.